Membranous glomerulonephritis

This phase 2 trial tests whether dapagliflozin, a drug used for diabetes and heart failure, can reduce harmful antibodies and prevent relapses in people with membranous nephropathy, an autoimmune kidney disease. The study enrolls 20 adults who have had a recent rise in anti-PLA2R…

This early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…

This early-phase study tests a new treatment using specially engineered immune cells (CD19 CAR-γδ T cells) for people with severe autoimmune kidney diseases like lupus nephritis, IgA nephropathy, and membranous nephropathy that haven't responded to standard therapies. About 15 pa…

This early-phase trial tests a new type of immune cell therapy called UCAR-T for people with a tough-to-treat kidney condition called refractory idiopathic membranous nephropathy. The therapy uses specially engineered cells to target and attack certain immune cells that may be dr…

This early-stage trial tests a new drug called YK012 in 66 adults with a severe form of kidney disease called primary membranous nephropathy that has not responded to standard treatments. YK012 is a bispecific antibody designed to reduce the immune system's attack on the kidneys.…

This early study tests a new drug called STR-P004 in 9 adults with immune-mediated kidney diseases. The goal is to see if the drug is safe and how the body processes it. Participants receive up to 8 infusions over 28 days, with possible dose increases. This is not a cure; it aims…

This study will observe 50 children (ages 1 month to 18 years) who come to the emergency room with kidney-related symptoms like swelling, blood in urine, or high blood pressure. Researchers want to learn which kidney diseases are most common and how children respond to initial tr…

This study aims to find genetic and protein markers that can predict whether patients with membranous nephropathy, a kidney disease, will respond to the drug rituximab. Researchers will analyze stored blood and tissue samples from 120 patients and healthy volunteers. The goal is …

This study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…